Grifols (GRFS) Competitors $9.94 +0.09 (+0.91%) Closing price 07/24/2025 04:00 PM EasternExtended Trading$10.04 +0.10 (+1.01%) As of 06:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. BNTX, INSM, SMMT, TEVA, ITCI, GMAB, MRNA, RDY, VTRS, and QGENShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include BioNTech (BNTX), Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Its Competitors BioNTech Insmed Summit Therapeutics Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Moderna Dr. Reddy's Laboratories Viatris Qiagen Grifols (NASDAQ:GRFS) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Do analysts prefer GRFS or BNTX? Grifols presently has a consensus price target of $10.30, indicating a potential upside of 3.62%. BioNTech has a consensus price target of $136.58, indicating a potential upside of 19.21%. Given BioNTech's higher possible upside, analysts plainly believe BioNTech is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.83 Does the media prefer GRFS or BNTX? In the previous week, BioNTech had 2 more articles in the media than Grifols. MarketBeat recorded 7 mentions for BioNTech and 5 mentions for Grifols. Grifols' average media sentiment score of 0.75 beat BioNTech's score of 0.40 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, GRFS or BNTX? Grifols has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.21B0.95$169.80M$1.178.50BioNTech$2.98B9.25-$719.92M-$3.40-33.70 Is GRFS or BNTX more profitable? Grifols has a net margin of 0.00% compared to BioNTech's net margin of -27.37%. Grifols' return on equity of 0.00% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A BioNTech -27.37%-3.94%-3.41% Do insiders & institutionals believe in GRFS or BNTX? 15.5% of BioNTech shares are owned by institutional investors. 0.2% of Grifols shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, GRFS or BNTX? Grifols has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. SummaryGrifols beats BioNTech on 9 of the 16 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.77B$2.77B$5.73B$9.47BDividend YieldN/A1.78%4.60%3.99%P/E Ratio8.509.1227.9819.95Price / Sales0.95736.18447.46100.93Price / Cash10.52166.2336.5558.97Price / Book0.735.228.655.90Net Income$169.80M$30.99M$3.24B$258.42M7 Day PerformanceN/A4.60%3.69%2.11%1 Month Performance16.80%12.70%10.34%12.44%1 Year Performance27.76%-0.48%34.36%19.55% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols3.8015 of 5 stars$9.94+0.9%$10.30+3.6%+28.6%$6.77B$7.21B8.5023,822Upcoming EarningsBNTXBioNTech1.4928 of 5 stars$111.00-1.7%$137.91+24.2%+37.8%$26.68B$2.98B-32.656,772INSMInsmed4.0761 of 5 stars$101.89+3.8%$108.07+6.1%+39.1%$19.33B$381.03M-17.121,271Positive NewsAnalyst ForecastInsider TradeSMMTSummit Therapeutics3.2355 of 5 stars$25.40+1.6%$34.67+36.5%+176.3%$18.86BN/A-74.70110Positive NewsTEVATeva Pharmaceutical Industries4.267 of 5 stars$16.43+0.2%$24.71+50.5%-0.8%$18.84B$16.54B-14.2836,830Positive NewsUpcoming EarningsGap UpITCIIntra-Cellular Therapies1.0348 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.0574 of 5 stars$21.46+0.3%$37.80+76.1%-15.2%$13.77B$3.12B12.192,682Positive NewsGap UpMRNAModerna4.2558 of 5 stars$32.87-2.3%$46.61+41.8%-71.2%$12.71B$3.24B-3.775,800Upcoming EarningsAnalyst ForecastRDYDr. Reddy's Laboratories2.8552 of 5 stars$14.58+0.4%$16.95+16.3%-8.1%$12.17B$325.54B22.0827,811Earnings ReportVTRSViatris2.4996 of 5 stars$9.14+0.2%$10.40+13.8%-20.1%$10.73B$14.74B-2.8832,000QGENQiagen3.7553 of 5 stars$48.25+0.3%$49.40+2.4%+25.6%$10.73B$1.98B120.985,765Positive NewsAnalyst Revision Related Companies and Tools Related Companies BNTX Alternatives INSM Alternatives SMMT Alternatives TEVA Alternatives ITCI Alternatives GMAB Alternatives MRNA Alternatives RDY Alternatives VTRS Alternatives QGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
